New drug trial aims to tame autoimmune diseases

NCT ID NCT06647069

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 30 times

Summary

This early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and the study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 001-201

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Investigational Site Number : 001-203

    RECRUITING

    Brisbane, Queensland, 4151, Australia

  • Investigational Site Number : 001-301

    RECRUITING

    Auckland, 0622, New Zealand

  • Investigational Site Number : 001-401

    RECRUITING

    Sarajevo, 71000, Bosnia and Herzegovina

  • Investigational Site Number : 001-402

    RECRUITING

    Mostar, 88000, Bosnia and Herzegovina

  • Investigational Site Number : 001-801

    RECRUITING

    Pretoria, 0002, South Africa

  • Investigational Site Number : 001-803

    RECRUITING

    Pretoria, 0184, South Africa

  • Investigational Site Number : 001-804

    RECRUITING

    Vereeniging, 1935, South Africa

Conditions

Explore the condition pages connected to this study.